TFA Therapeutics (RAJAF) Receivables - Net (2020 - 2023)

TFA Therapeutics has reported Receivables - Net for 3 years, with the latest figure at $21869.0 in Q3 2023.

• On a quarterly basis, Receivables - Net changed N/A year-over-year to $21869.0 in Q3 2023; TTM through Sep 2023 was $21869.0, a N/A change from a year earlier, with the FY2024 full-year figure at $305.0, changed N/A from the prior year.
• Receivables - Net was $21869.0 for Q3 2023 at TFA Therapeutics, down from $358006.0 in the prior quarter.
• The five-year high for Receivables - Net was $358006.0 in Q4 2021, with the low at $21869.0 in Q3 2023.
• Average Receivables - Net over 3 years is $206985.7, with a median of $241082.0 recorded in 2020.
• The largest YoY upside for Receivables - Net was 48.5% in 2021 against a maximum downside of 48.5% in 2021.
• Over 3 years, Receivables - Net stood at $241082.0 in 2020, then surged by 48.5% to $358006.0 in 2021, then sank by 93.89% to $21869.0 in 2023.
• The last three Receivables - Net figures came in at $21869.0 (Q3 2023), $358006.0 (Q4 2021), and $241082.0 (Q4 2020), per Business Quant data.